Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...